A new report uses a decades-old brand-name drug to expose a feature in Medicare Part D that could undermine generic competition for specialty drugs. The feature, which drug price watchdog 46Brooklyn calls a flaw, makes expensive specialty brands cheaper to both beneficiaries and insurers than generic counterparts, but taxpayers pay more because of it. Copaxone was approved in 1996, and generic competitors hit the market in 2015 and 2017, yet the brand multiple sclerosis drug generated $1.2 billion in Part...